Bullous pemphigoid triggered by
            <scp>COVID</scp>
            ‐19 vaccine: Rapid resolution with corticosteroid therapy

Dell'Antonia, Massimo; Anedda, Speranza Luisa; Usai, Federica; Atzori, Laura; Ferreli, Caterina

doi:10.1111/dth.15208

Cited by 20 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Median age at onset (81 years) was in line with published observations [82.5 (IQR: 71.25-84.75) years; n = 24/34 with age available] (23-28). Likewise, sex distribution showed a slight male sex preference in both our cohort (M:F = 1.3) and available reports (M:F = 1.2; n = 22 with gender available) (23)(24)(25)(26)(27)(28).…”

Section: Discussionsupporting

confidence: 69%

“…Our sample size prevents the possibility to reliably compare different treatments. However, most of the subjects were easily controlled with treatment regimens concepted for milder forms of BP (i.e., topical steroids, lowto-moderate doses of systemic corticosteroids, doxycycline), supporting the assumption that the majority of COVID-19 induced BP cases would be non-severe (17,(24)(25)(26). Systemic corticosteroids as well as immunosuppressive adjuvants required to achieve disease control in BP may affect the efficacy of anti-SARS-CoV-2 vaccines.…”

Section: Discussionmentioning

confidence: 87%

“…Clinically, the presentation of SARS-CoV-2-vaccine-associated BP appears to be typical with tense bullae on an erythematous base, various degrees of cutaneous involvement, and an overall benign course with appropriate treatment (only patient n. 21 had stable disease at 3 months). Although many published reports describe a similarly favorable course ( 17 , 24 – 28 ), in the study by Tomayko et al ., five patients had ongoing disease after a follow-up period ranging from 23 to 105 days ( 12 ). Our sample size prevents the possibility to reliably compare different treatments.…”

Section: Discussionmentioning

confidence: 91%

“…SARS-CoV-2-vaccine-associated cutaneous eruptions encompass a growing spectrum of clinicopathological varieties, including local injection site reactions, urticarial eruptions, morbilliform eruptions, pernio/chilblain-like lesions, cosmetic filler reactions, herpes zoster and herpes simplex flares, pityriasis rosea-like eruptions (11,20,21). Autoimmune bullous skin diseases have also been observed following SARS-CoV-2-vaccination, with approximately 34 individual cases of vaccine-associated BP currently described (12,14,17,(22)(23)(24)(25)(26)(27)(28) (Supplementary Table 1). According to the registry-based studies by McMahon et al, BP-like eruptions accounted for 20% (12/58) of biopsy-proven SARS-CoV-2-vaccine-associated cutaneous reactions and 1.5% overall (11,22).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza, pneumococcus, meningococcus, hepatitis B and rabies. The putative mechanism by which COVID-19-vaccines may induce BP has not been clarified. An Italian multicentre study was conducted to collect clinical, histopathological and immunopathological data of patients with BP associated with COVID-19-vaccines. Twenty-one cases were collected, including 9 females and 12 males (M/F = 1.3) with a median age at diagnosis of 82 years. Seventeen patients received the COMIRNATY Pfizer-BioNTech vaccine, two the Moderna mRNA-1273 vaccine, one the ChAdOx1/nCoV-19-AstraZeneca/ Vaxzevria vaccine and one received the first dose with the ChAdOx1/nCoV-19-AstraZeneca/Vaxzevria vaccine and the second dose with the COMIRNATY Pfizer-BioNTech vaccine. Median latency time between the first dose of anti-SARS-CoV-2 vaccine and the onset of cutaneous manifestations was 27 days. Median BPDAI at onset was 42. Eleven out of seventeen patients (65%) had positive titres for anti-BP180 antibodies with a median value of 106.3 U/mL on ELISA; in contrast, only five out of seventeen (29%) were positive for anti-BP230 antibodies, with a median of 35.3 U/mL. In conclusion, in terms of mean age, disease severity at diagnosis and clinical phenotype vaccine-associated BP patients seem to be similar to idiopathic BP with an overall benign course with appropriate treatment. On the other hand, the slight male predominance and the reduced humoral response to BP230 represent peculiar features of this subset of patients.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Alopecia areata (AA) [74], bullous pemphigoid [75], COVID arm (local injection site reaction) [76,77], eosinophilic cellulitis (Wells syndrome) [22], eosinophilic panniculitis [24], erythema multiforme [78], herpes zoster (skin, oral and facial palsy) [53,57,79,80], leukocytoclastic vasculitis [81], non-episodic angioedema with eosinophilia [23], psoriasis [82], Stevens-Johnson syndrome [83], subacute cutaneous lupus erythematosus [11,84,85], and urticaria [77] have been reported following COVID-19 vaccination (Table 1). AA is an autoimmune disease, and an increase in IFN-γ and inflammatory cytokines, including IL-6 and IL-1β, have been reported [86].…”

Section: Skin Diseasesmentioning

confidence: 99%

What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions

et al. 2022

View full text Add to dashboard Cite

COVID-19 vaccines have been used to counteract the global COVID-19 pandemic. While these are effective, adverse reactions have been reported, such as injection-site pain, muscle ache, fever, palpitation, and chest discomfort. The release of inflammatory cytokines, such as interleukin (IL)-6 and IL-1β, is a potential mechanism for post-vaccine side-effects. Chest discomfort after the vaccination, including myocarditis and acute coronary syndrome, is a particularly serious adverse reaction. It is important to be familiar with the differential diagnoses of chest discomfort and organ-specific diseases associated with COVID-19 vaccines as the preparation for booster shots and vaccinations among children aged 5–11 years begins. High-intensity exercise, alcohol, tobacco smoking, and baths promote inflammatory cytokines, such as IL-6, which may exacerbate the adverse reactions after vaccination. Japanese data show that deaths during baths are the most common for several days after mRNA vaccination. Additionally, alcohol and tobacco smoking were identified as predictive factors of lower antibody titers after vaccination. In this review, we aimed to provide a few recommendations to prevent vaccine-associated disease.

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

Bullous pemphigoid triggered by COVID ‐19 vaccine: Rapid resolution with corticosteroid therapy

Cited by 20 publications

References 14 publications

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions

Tozinameran

Contact Info

Product

Resources

About